AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32401302
Drug: Human milk
RxNorm normalized name: HUMAN MILK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human milk insulin and leptin
Trial: 32401707
Drug: 0.5 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL/kg 0.25% bupivacaine (Group B)
Trial: 32401707
Drug: 0.5 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL/kg 0.25% bupivacaine + 3 mg/kg 1% lidocaine (Group BL)
Trial: 32401707
Drug: Intra-operative intravenous
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-operative intravenous fentanyl use
Trial: 32401731
Drug: Braden Pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Braden Pressure Ulcer Risk Assessment conducted weekly.
Trial: 32401744
Drug: Revefenacin (LAMA)
DrugBank: Revefenacin (DB11855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Revefenacin (LAMA) and Formoterol Fumarate (LABA) inhalation solution admixture
Trial: 32403379
Drug: Liposomal anthralin
RxNorm normalized name: Anthralin
DrugBank: Anthralin (DB11157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal anthralin gel
Trial: 32403379
Drug: Ethosomal anthralin
RxNorm normalized name: Anthralin
DrugBank: Anthralin (DB11157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethosomal anthralin gel
Trial: 32404003
Drug: Transference work
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transference work in psychodynamic therapy
Trial: 32404091
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment of pancreatic metastases
Trial: 32404437
Drug: Oral amoxicillin
RxNorm normalized name: amoxicillin Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amoxicillin at 75-100 mg/kg/day divided doses
Trial: 32404868
Drug: Radium-223 with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radium-223 with bone health agents (BHAs)
Trial: 32405431
Drug: Phosphorus supplementation
RxNorm normalized name: Phosphorus
DrugBank: Phosphorus (DB14151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphorus supplementation (400 mg) with glucose
Trial: 32405623
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg albendazole (PSAC)
Trial: 32405623
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg albendazole (SAC)
Trial: 32405623
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg albendazole (Adults)
Trial: 32407157
Drug: Invasive Tracheobronchial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive Tracheobronchial Aspergillosis treatment; specific intervention details not available
Trial: 32407400
Drug: Maternal genetic
RxNorm normalized name: Burosumab (genetical recombination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal genetic locus ITPR1 (rs746039 [G])
Trial: 32407591
Drug: Guselkumab 200
RxNorm normalized name: guselkumab 200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab 200 mg (subcutaneous)
Trial: 32407591
Drug: Probe cocktail
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probe cocktail (midazolam, S-warfarin, omeprazole, dextromethorphan, caffeine)
Trial: 32408984
Drug: Chimeric Antigen
RxNorm normalized name: Chimeric antigen receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimeric Antigen Receptor T-Cells (CAR-T)
Trial: 32410049
Drug: Transdiagnostic adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdiagnostic adherence counseling and cognitive behavioral therapy
Trial: 32410080
Drug: Capmatinib 400
RxNorm normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capmatinib 400 mg twice daily plus cetuximab (weekly intravenous at approved dose)
Trial: 32410080
Drug: Capmatinib (150,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capmatinib (150, 300, and 400 mg) plus cetuximab
Trial: 32410617
Drug: Model-based personalized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model-based personalized robot-aided rehabilitation therapy
Trial: 32410670
Drug: Dialectical Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical Behaviour Therapy (DBT) implementation
Trial: 32411374
Drug: 16-week supervised
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 16-week supervised heavy resistance training program with weekly undulating periodization
Trial: 32411381
Drug: Behavioral activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral activation group therapy (BA) in addition to usual care
Trial: 32411717
Drug: Intravenous Cyclophosphamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Cyclophosphamide, dosage and duration not available
Trial: 32412142
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D sufficient group (serum 25OHD ≥ 20 ng/mL)
Trial: 32412142
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D insufficient group (serum 25OHD 10-20 ng/mL)
Trial: 32412142
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D deficient group (serum 25OHD ≤ 10 ng/mL)
Trial: 32412142
Drug: Serum 25OHD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum 25OHD < 20 ng/mL
Trial: 32412142
Drug: Serum 25OHD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum 25OHD ≥ 20 ng/mL
Trial: 32414330
Drug: Bioresorbable polymer
RxNorm normalized name: dicresulene polymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioresorbable polymer drug-eluting stent (BP-DES)
Trial: 32414346
Drug: Ready-to-use food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ready-to-use food (RUF) provided according to WHO prescription weight- and age-bands for a maximum of 9-12 months.
Trial: 32414346
Drug: Ready-to-use food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ready-to-use food (RUF) provided according to WHO prescription weight- and age-bands.
Trial: 32414827
Drug: Centralised Chronic
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Centralised Chronic Medication Dispensing and Distribution (CCMDD) programme
Trial: 32414848
Drug: Entospletinib +
RxNorm normalized name: Entospletinib
DrugBank: Entospletinib (DB12121)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entospletinib + Vincristine chemotherapy
Trial: 32414850
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP)
Trial: 32415705
Drug: Direct oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct oral anticoagulants (DOACs) - high-dose
Trial: 32415705
Drug: Direct oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct oral anticoagulants (DOACs) - low-dose
Trial: 32415708
Drug: HSK3486 (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK3486 (0.4 mg/kg)
Trial: 32416764
Drug: Panitumumab-IRDye800CW 25
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab-IRDye800CW 25 mg
Trial: 32416764
Drug: Panitumumab-IRDye800CW 50
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab-IRDye800CW 50 mg
Trial: 32416764
Drug: Panitumumab-IRDye800CW 75
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab-IRDye800CW 75 mg
Trial: 32416764
Drug: Panitumumab-IRDye800CW (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panitumumab-IRDye800CW (all doses)
Trial: 32418789
Drug: PCV13 vaccination
RxNorm normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCV13 vaccination (3 doses with a minimum of 1 month interval between treatment courses)
Trial: 32419586
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of antiplatelet therapy (APT) during noncardiac surgery
Trial: 32419586
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of antiplatelet therapy (APT) during noncardiac surgery
Trial: 32419679
Drug: Valbenazine 40
RxNorm normalized name: valbenazine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valbenazine 40 mg/day, escalated to 80 mg/day after week 4 based on tolerability and clinical assessment of TD.
Trial: 32419949
Drug: Combined bowel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined bowel preparation (2L polyethylene glycol solution night before CE, 5mL simethicone and 5mg metoclopramide 20 minutes prior to CE, right lateral position 30 minutes after swallowing CE)
Trial: 32420402
Drug: Artemisinin-based combination
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin-based combination therapies
Trial: 32423477
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with epirubicin/docetaxel for 6 cycles, supplemented with bevacizumab in cycles 3-6
Trial: 32423837
Drug: Pembrolizumab 200mg
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab 200mg intravenously every 3 weeks until confirmed progression, intolerable toxicity, patient withdrawal, or 24 months of therapy.
Trial: 32424028
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no antimalarial treatment)
Trial: 32425736
Drug: GBCK25 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GBCK25 (500 mg/day)
Trial: 32425736
Drug: GBCK25 (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GBCK25 (125 mg/day)
Trial: 32425926
Drug: T cell-based
RxNorm normalized name: tisagenlecleucel
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T cell-based immunotherapy targeting alpha-fetoprotein (AFP)
Trial: 32427279
Drug: Early corticosteroid
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early corticosteroid (methylprednisolone 0.5 to 1 mg/kg/day for 3 days)
Trial: 32427581
Drug: IgG antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG antibodies against CIDRα1.7 and CIDRα1.8
Trial: 32427581
Drug: IgG antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG antibodies against CIDRγ3
Trial: 32428369
Drug: Susceptibility-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Susceptibility-guided therapy (14-day triple or quadruple therapy based on susceptibility to clarithromycin, levofloxacin, and metronidazole)
Trial: 32428369
Drug: All regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All regimens of susceptibility-guided therapy
Trial: 32428369
Drug: Empiric classical
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Empiric classical bismuth quadruple therapy
Trial: 32428543
Drug: Nitric Oxide-Releasing
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric Oxide-Releasing Topical Medication
Trial: 32429000
Drug: Gepotidacin 750
RxNorm normalized name: gepotidacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gepotidacin 750 mg IV over 2 hours
Trial: 32429939
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behavioral therapy for BDD
Trial: 32430018
Drug: Chia supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chia supplementation (25 g/day)
Trial: 32430019
Drug: FACT-M questionnaire
RxNorm normalized name: m-phenylenediamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FACT-M questionnaire in treatment-naïve patients (Part B)
Trial: 32430395
Drug: Intravenous alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alteplase (0.9 mg/kg of body weight)
Trial: 32430416
Drug: Daily FOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily FOT parameters (resistance (R) and reactance (X))
Trial: 32430415
Drug: Microbiome-based therapies;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microbiome-based therapies; details on dosage and duration not available.
Trial: 32430415
Drug: Host-targeted therapeutics;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Host-targeted therapeutics; details on dosage and duration not available.
Trial: 32430583
Drug: Folic polyglutamate
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic polyglutamate tablets (oral) and 500 mL of a 10% mannitol solution (intravenous) before the injection of 3.7-5.5 GBq of radioligand therapy (RLT)
Trial: 32430583
Drug: Radioligand therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioligand therapy (RLT) with 3.7-5.5 GBq
Trial: 32435020
Drug: C1 inhibitor
RxNorm normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: C1 inhibitor (C1-INH) 1000U administered biweekly via intravenous infusion
Trial: 32435020
Drug: C1 inhibitor
RxNorm normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: C1 inhibitor (C1-INH)
Trial: 32436060
Drug: PF-06840003 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06840003 (500 mg BID)
Trial: 32436060
Drug: PF-06840003 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06840003 (various doses)
Trial: 32436335
Drug: Sofosbuvir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir (400 mg/d) plus Daclatasvir with or without Ribavirin (1-1.2 g/d) for 12 weeks
Trial: 32436335
Drug: Sofosbuvir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir (400 mg/d) plus Daclatasvir with or without Ribavirin (1-1.2 g/d) for 24 weeks
Trial: 32436923
Drug: sTILs as
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sTILs as an integral biomarker in a single-center phase II immunotherapy trial (TONIC trial, NCT02499367).
Trial: 32437557
Drug: dihydroartemisinin/piperaquine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dihydroartemisinin/piperaquine (4 mg/kg/day for 3 days)
Trial: 32437557
Drug: artesunate monotherapy
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: artesunate monotherapy followed by dihydroartemisinin/piperaquine (4 mg/kg/day for 3 days)
Trial: 32437664
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg flat dose IV) + Trastuzumab (8 mg/kg loading dose IV) + chemotherapy
Trial: 32437664
Drug: Pembrolizumab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab + Trastuzumab + chemotherapy
Trial: 32437738
Drug: Midostaurin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midostaurin treatment
Trial: 32439432
Drug: Low-dose capsaicin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose capsaicin (0.01 mM) nasal spray
Trial: 32439432
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for idiopathic rhinitis
Trial: 32439700
Drug: iNeo-Vac-P01 (neoantigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iNeo-Vac-P01 (neoantigen vaccine)
Trial: 32440228
Drug: Ethinylestradiol 20
RxNorm normalized name: Ethinylestradiol 20 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethinylestradiol 20 μg/Drospirenone 3 mg
Trial: 32440228
Drug: Post-treatment SF-36v2
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment SF-36v2 scores
Trial: 32441892
Drug: Low-dose apatinib
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose apatinib (500 mg or 250 mg per day)
Trial: 32442637
Drug: Comparator software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator software solutions
Trial: 32442785
Drug: Oral rigosertib
RxNorm normalized name: Rigosertib
DrugBank: Rigosertib (DB12146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rigosertib (140 mg twice daily, 280 mg twice daily, or 840 mg/day [560 mg morning/280 mg evening]) for 3 weeks of a 4-week cycle
Trial: 32442785
Drug: Parenteral azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Parenteral azacitidine (75 mg/m2)
Trial: 32443041
Drug: Oral Glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Glucose Tolerance Test (OGTT) performed between 2.5 and 3.5 months of age.
Trial: 32443041
Drug: Abnormal OGTT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abnormal OGTT defined as early hyperglycaemia (>1.8 g/L until 30 minutes; >1.7 g/L between 30 minutes and 2 hours; and >1.4 g/L between 2 and 3 hours) and/or late hypoglycaemia (<0.6 g/L after 2 hours).
Trial: 32444192
Drug: Direct venous
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct venous inoculation (DVI) of PfSPZ Vaccine (0.5 mL)
Trial: 32444192
Drug: Direct venous
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct venous inoculation (DVI) of PfSPZ Vaccine
Trial: 32444241
Drug: Daily multivitamin/micronutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily multivitamin/micronutrients supplement
Trial: 32444411
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron supplementation with ferric maltol
Trial: 32444417
Drug: Cediranib plus
RxNorm normalized name: cediranib
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cediranib plus Olaparib (Olaparib 300 mg twice daily + Cediranib 20 mg once daily)
Trial: 32445848
Drug: Prolonged hospitalization,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged hospitalization, smoking, and preoperative opioid prescriptions
Trial: 32446108
Drug: Sertraline +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline + Prolonged Exposure (SERT + PE)
Trial: 32446108
Drug: Sertraline +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline + Enhanced Medication Management (SERT + EMM)
Trial: 32446716
Drug: Non-selective beta-blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-selective beta-blockers (NSBBs)
Trial: 32447411
Drug: Melanoma targeted
RxNorm normalized name: melanoma vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melanoma targeted radionuclide therapy (TRT)
Trial: 32447421
Drug: PG-11047, 60-min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PG-11047, 60-min intravenous infusions, doses ranging from 50 to 750 mg, administered on days 1, 8, and 15 of a 28-day cycle
Trial: 32448349
Drug: 2-hour plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-hour plasma glucose (2-h PG) after a 75-g oral glucose tolerance test
Trial: 32448380
Drug: Adjusted HLH-2004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted HLH-2004 criteria cutoffs (hyperferritinemia to 3000 μg/L and fever to 38.2 °C)
Trial: 32448902
Drug: Raltegravir 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 12 mg/kg twice daily (administered after crushing)
Trial: 32449684
Drug: Group Cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Cognitive Behavioral Therapy (CBT) plus Treatment-As-Usual (TAU)
Trial: 32449684
Drug: Group Exercise
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Exercise plus Treatment-As-Usual (TAU)
Trial: 32449684
Drug: Wait-listing to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wait-listing to receive Treatment-As-Usual (TAU) only
Trial: 32449927
Drug: Optimized criteria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized criteria (PAC >20 ng/dL, PRC <2.5 μIU/mL, hypokalemia)
Trial: 32451120
Drug: Efavirenz 400
RxNorm normalized name: efavirenz 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz 400 mg once daily for CYP2B6 516 GG genotype
Trial: 32451120
Drug: Efavirenz 300
RxNorm normalized name: efavirenz 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz 300 mg once daily for CYP2B6 516 GT genotype
Trial: 32451120
Drug: Efavirenz 100
RxNorm normalized name: efavirenz 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz 100 mg once daily for CYP2B6 516 TT genotype